Royalty Pharma (RPRX) Retained Earnings (2020 - 2026)

Royalty Pharma (RPRX) has 7 years of Retained Earnings data on file, last reported at $2.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 40.46% year-over-year to $2.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (down 40.46% YoY), and the FY2025 full-year result was $4.1 billion, up 44.89% from the prior year.
• Retained Earnings eased to $2.5 billion in Q1 2026, from $4.1 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $4.2 billion in Q1 2025 to a low of $12.3 million in Q1 2022.
• A 5-year average of $3.1 billion and a median of $3.6 billion in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings sank 58.22% in 2022 and soared 17916.99% in 2023, its largest moves.
• Tracing RPRX's Retained Earnings over 5 years: stood at $3.7 billion in 2022, then advanced by 9.42% to $4.0 billion in 2023, then dropped by 29.06% to $2.8 billion in 2024, then soared by 44.89% to $4.1 billion in 2025, then slumped by 39.19% to $2.5 billion in 2026.
• Business Quant data shows RPRX's Retained Earnings at $2.5 billion in Q1 2026, $4.1 billion in Q4 2025, and $4.1 billion in Q3 2025.